Verschoor, Arie Jan http://orcid.org/0000-0001-9972-4241
Litière, Saskia http://orcid.org/0000-0002-6433-4056
Marréaud, Sandrine http://orcid.org/0000-0002-3205-3858
Judson, Ian http://orcid.org/0000-0002-4766-5304
Toulmonde, Maud http://orcid.org/0000-0003-3896-9274
Wardelmann, Eva http://orcid.org/0000-0001-6788-4910
LeCesne, Axel
Gelderblom, Hans http://orcid.org/0000-0001-9270-8636
Funding for this research was provided by:
European Organisation for Research and Treatment of Cancer
Article History
Received: 20 January 2020
Accepted: 14 August 2020
First Online: 9 September 2020
Ethics approval and consent to participate
: All patients consented to participate in the different trials. For all studies, ethical approval was provided by the medical ethical committees of the different participating hospitals. Information about the ethics approval is provided in the manuscripts of the individual studies.
: Not applicable.
: AJV, SL, SM, IJ, MT and HG have nothing to disclose. ALC reports personal fees from Pharmamar, Lilly, Novartis and Amgen, all outside the submitted work. EW reports personal fees from Novartis, Lilly, Nanobiotix, Bayer, PharmaMar, Milestone, Menarini and New Oncology, all outside the submitted work.